Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.85, moving -3.27% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.33%. On ...

Visualization has become one of the most important training tools for athletes in bobsleigh, luge and skeleton at the 2026 Milan Cortina Olympics. With limited access to real tracks, competitors rely ...

Recursion Pharmaceuticals Inc. stock reached a new 52-week low, closing at $3.53, just pennies away from its absolute 52-week bottom of $3.54. This milestone marks a significant downturn for the ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

This second course of the Data-Driven Decision Making (DDDM) series provides a high-level overview of data analysis and visualization tools, preparing learners to discuss best practices and develop an ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Soil microbiology is enjoying a period of challenge and discovery made possible by the availability of new approaches for characterizing microbial communities and for imaging the soil environment.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...